51³ΙΘΛΆ―Βώ

Meeting Coverage

ESMO Video Pearls

Video Pearls from the European Society for Medical Oncology

Nicholas Rohs, MD, on the Clinical Implications and Limitations of the IPSOS Trial

Atezolizumab outperforms chemo in poor-prognosis non-small cell lung cancer

image

Latest ESMO Video Pearls Meeting Coverage

How Air Pollution Can Trigger NSCLC in Never-Smokers

Study is "a big call-out for us to fight for improved air quality," says Nicholas Rohs, MD

October 4, 2022
Targeted Agent Bests Chemo in Second-Line for KRAS-Mutant NSCLC

"Unfortunately, it's not a home run," says Roy Herbst, MD, PhD

September 27, 2022
ADAURA Update: Osimertinib Benefit in Early NSCLC Sustained

It's "full speed ahead" for EGFR-positive patients, says Roy Herbst

September 20, 2022
No Survival Benefit Seen With Regorafenib in Advanced Chordoma

But James Hu, MD, says he is encouraged that a randomized study was done for this rare tumor

October 14, 2021
Doxorubicin-Trabectedin Impresses in Leiomyosarcoma

Combination increased PFS as first-line treatment but has expected added toxicities

October 7, 2021
Sarcoma Highlights From ESMO 2021

Edwin Choy briefly describes several abstracts that caught his attention

September 30, 2021
'Real Breakthrough' at ESMO 2020 Is Cervical Cancer

Bradley Monk, MD, details five potential FDA approvals on the horizon

October 14, 2020
MEDIOLA Examines Triplet Therapy in Ovarian Cancer

New cohort adds bevacizumab to olaparib /durvalumab combo

October 7, 2020